Article Text

Download PDFPDF
Antipsychotic medications do not differ substantially in ability to reduce violent behaviour in people with schizophrenia

Statistics from



Do antipsychotic medications differ in the ability to reduce violent behaviour in people with schizophrenia?


1493 adults with schizophrenia (DSM-IV), aged 18–65 years. Detailed inclusion and exclusion criteria are not reported in this article.


The NIMH Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) project; 57 US sites (academic and community); January 2001–December 2004.


Olanzapine (7.5 mg capsule), quetiapine (200 mg capsule), risperidone (1.5 mg), perphenazine (8 mg capsule) or ziprasidone (40 mg capsule). Doses were altered according to clinical judgement, with up to 4 capsules given daily.


Primary outcome: change in violent behaviour from baseline to 6 months (MacArthur Community Violence Interview—a combined measure of minor (eg, assault without injury) and serious (eg, assault with a weapon) violent behaviours). Information was collected from both the participant and family members.

Patient follow-up:

45% of participants completed 6 months of treatment and were included in the retained sample; 97% were included in the intention to treat (ITT) sample (48 participants were excluded …

View Full Text


  • Source of funding: National Institute of Mental Health and Foundation of Hope of Raleigh. Study medications were donated by the manufacturers.

  • ▸ Additional notes and a reference list are published online only at


  • Competing interests: None.

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.